Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Cash from Investing Activities (2010 - 2020)

Grifols' (GRFS) quarterly Cash from Investing Activities came in at -$125.1 million in Q1 2020, up 56.61% YoY from -$79.9 million in Q2 2019, and up 71.26% on a QoQ basis from -$435.2 million in Q4 2019.

Grifols (GRFS) Cash from Investing Activities (2010 - 2020) Analysis & Trends

Grifols (GRFS) has 11 years of Cash from Investing Activities data on file, last reported at -$125.1 million in Q1 2020.

  • Quarterly Cash from Investing Activities rose 56.61% year-over-year to -$125.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$94.3 million (down 223.87% YoY) and the FY2025 annual result came in at -$674.0 million, down 171.19% from the prior year.
  • Cash from Investing Activities climbed to -$125.1 million in Q1 2020, from -$435.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $2.4 billion in Q4 2017 to a low of -$798.7 million in Q3 2016.
  • A 5-year average of $281.0 million and a median of -$120.2 million in 2016 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2016 — Cash from Investing Activities sank 1045.5% — and 2017, when it soared 2116.99%.
  • Tracing GRFS's Cash from Investing Activities over 5 years: stood at -$120.2 million in 2016, then soared by 2116.99% to $2.4 billion in 2017, then plunged by 68.9% to $754.2 million in 2018, then slumped by 157.7% to -$435.2 million in 2019, then jumped by 71.26% to -$125.1 million in 2020.
  • The last three Cash from Investing Activities figures came in at -$125.1 million (Q1 2020), -$435.2 million (Q4 2019), and -$288.3 million (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -1.11 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -1.20 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -5.60 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -3.11 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -2.91 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -569.00 Mn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.35 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 2.11 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 2.68 Bn
10 Grifols 5.45 Bn 4.45 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2020 -125.09 Mn
Mar 31, 2020 -125.09 Mn
Dec 31, 2019 -435.16 Mn
Dec 31, 2019 -435.16 Mn
Mar 31, 2019 -288.25 Mn
Mar 31, 2019 -288.25 Mn
Dec 31, 2018 754.17 Mn
Dec 31, 2018 754.17 Mn
Jun 30, 2018 -509.49 Mn
Jun 30, 2018 -509.49 Mn
Mar 31, 2018 119.73 Mn
Mar 31, 2018 119.73 Mn
Dec 31, 2017 2.43 Bn
Dec 31, 2017 2.43 Bn
Jun 30, 2017 88.45 Mn
Jun 30, 2017 88.45 Mn
Mar 31, 2017 1.98 Bn
Mar 31, 2017 1.98 Bn
Dec 31, 2016 -120.24 Mn
Dec 31, 2016 -120.24 Mn